{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T01:58:16Z","timestamp":1767664696978,"version":"3.37.3"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,10,14]],"date-time":"2021-10-14T00:00:00Z","timestamp":1634169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,10,14]],"date-time":"2021-10-14T00:00:00Z","timestamp":1634169600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2022,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>The immune checkpoint inhibitor nivolumab is commonly used for non-small-cell lung cancer treatment. Immune checkpoint inhibitors cause immune-related adverse events, including interstitial pneumonia. However, there are no studies on the risk factors for interstitial pneumonia exacerbation after immune checkpoint inhibitor administration in patients with a history of different types of interstitial pneumonia. Therefore, we aimed to investigate the risk factors for interstitial pneumonia exacerbation in patients with non-small-cell lung cancer and a history of interstitial pneumonia. We also aimed to explore differences in the risk of interstitial pneumonia exacerbation due to various types of interstitial pneumonia\u2014idiopathic interstitial pneumonia, immune-related pneumonitis, and radiation pneumonitis.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Eleven patients with a history of interstitial pneumonia exacerbation following the administration of immune checkpoint inhibitor were included in the study. We performed 1:2 matching based on age and sex. Twenty-two patients whose interstitial pneumonia did not worsen after immune checkpoint inhibitor administration belonged to the control group. We calculated odds ratios for each factor in the patients and control subjects.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The odds ratio of idiopathic interstitial pneumonia in the case group was 0.15 (95% confidence interval: 0.03\u20130.89) (<jats:italic>p<\/jats:italic>\u2009=\u20090.03). There were no significant differences in other factors, such as smoking history, pulmonary emphysema, and chronic obstructive pulmonary disease.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>The administration of immune checkpoint inhibitors in non-small-cell lung cancer patients with a history of idiopathic interstitial pneumonia might be a viable treatment option and have clinical benefits.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00280-021-04362-7","type":"journal-article","created":{"date-parts":[[2021,10,14]],"date-time":"2021-10-14T06:04:58Z","timestamp":1634191498000},"page":"21-30","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Safety of immune checkpoint inhibitors in non-small-cell lung cancer patients with idiopathic interstitial pneumonia: a matched case\u2013control study"],"prefix":"10.1007","volume":"89","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4731-6032","authenticated-orcid":false,"given":"Takenori","family":"Ichimura","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miwa","family":"Hinata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daisuke","family":"Ichikura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinya","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,10,14]]},"reference":[{"key":"4362_CR1","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1093\/annonc\/mdy275","volume":"29","author":"D Planchard","year":"2018","unstructured":"Planchard D, Popat S, Kerr K, Novello S, Smit EF, Faivre-Finn C, Mok TS, Reck M, Van Schil PE, Hellmann MD, Peters S, ESMO Guidelines Committee (2018) Metastatic non-small cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 29:192\u2013237. https:\/\/doi.org\/10.1093\/annonc\/mdy275 (Suppl 4)","journal-title":"Ann Oncol"},{"key":"4362_CR2","doi-asserted-by":"publisher","first-page":"738","DOI":"10.3390\/cancers12030738","volume":"12","author":"RK Vaddepally","year":"2020","unstructured":"Vaddepally RK, Kharel P, Pandey R, Garje R, Chandra AB (2020) Review of indications of FDA-approved immune checkpoint inhibitors per NCCN guidelines with the level of evidence. Cancers (Basel) 12:738. https:\/\/doi.org\/10.3390\/cancers12030738","journal-title":"Cancers (Basel)"},{"key":"4362_CR3","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1007\/s10147-019-01431-z","volume":"24","author":"H Akamatsu","year":"2019","unstructured":"Akamatsu H, Ninomiya K, Kenmotsu H, Morise M, Daga H, Goto Y, Kozuki T, Miura S, Sasaki T, Tamiya A, Teraoka S, Tsubata Y, Yoshioka H, Hattori Y, Imamura CK, Katsuya Y, Matsui R, Minegishi Y, Mizugaki H, Nosaki K, Okuma Y, Sakamoto S, Sone T, Tanaka K, Umemura S, Yamanaka T, Amano S, Hasegawa K, Morita S, Nakajima K, Maemondo M, Seto T, Yamamoto N (2019) The Japanese Lung Cancer Society guideline for non-small cell lung cancer, stage IV. Int J Clin Oncol 24:731\u2013770. https:\/\/doi.org\/10.1007\/s10147-019-01431-z","journal-title":"Int J Clin Oncol"},{"key":"4362_CR4","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s11912-020-0897-9","volume":"22","author":"EP Darnell","year":"2020","unstructured":"Darnell EP, Mooradian MJ, Baruch EN, Yilmaz M, Reynolds KL (2020) Immune-related adverse events (irAEs): diagnosis, management, and clinical pearls. Curr Oncol Rep 22:39. https:\/\/doi.org\/10.1007\/s11912-020-0897-9","journal-title":"Curr Oncol Rep"},{"key":"4362_CR5","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1056\/nejmoa1507643","volume":"373","author":"H Borghaei","year":"2015","unstructured":"Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, Chow LQ, Vokes EE, Felip E, Holgado E, Barlesi F, Kohlh\u00e4ufl M, Arrieta O, Burgio MA, Fayette J, Lena H, Poddubskaya E, Gerber DE, Gettinger SN, Rudin CM, Rizvi N, Crin\u00f2 L, Blumenschein GR, Antonia SJ, Dorange C, Harbison CT, Graf Finckenstein F, Brahmer JR (2015) Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 373:1627\u20131639. https:\/\/doi.org\/10.1056\/nejmoa1507643","journal-title":"N Engl J Med"},{"key":"4362_CR6","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1056\/nejmoa1606774","volume":"375","author":"M Reck","year":"2016","unstructured":"Reck M, Rodr\u00edguez-Abreu D, Robinson AG, Hui R, Cs\u0151szi T, F\u00fcl\u00f6p A, Gottfried M, Peled N, Tafreshi A, Cuffe S, O\u2019Brien M, Rao S, Hotta K, Leiby MA, Lubiniecki GM, Shentu Y, Rangwala R, Brahmer JR, KEYNOTE-024 Investigators (2016) Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med 375:1823\u20131833. https:\/\/doi.org\/10.1056\/nejmoa1606774","journal-title":"N Engl J Med"},{"key":"4362_CR7","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/s0140-6736(16)32517-x","volume":"389","author":"A Rittmeyer","year":"2017","unstructured":"Rittmeyer A, Barlesi F, Waterkamp D, Park K, Ciardiello F, von Pawel J, Gadgeel SM, Hida T, Kowalski DM, Dols MC, Cortinovis DL, Leach J, Polikoff J, Barrios C, Kabbinavar F, Frontera OA, De Marinis F, Turna H, Lee JS, Ballinger M, Kowanetz M, He P, Chen DS, Sandler A, Gandara DR, OAK Study Group (2017) Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet 389:255\u2013265. https:\/\/doi.org\/10.1016\/s0140-6736(16)32517-x","journal-title":"Lancet"},{"key":"4362_CR8","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.3389\/fonc.2020.01785","volume":"10","author":"S Zhu","year":"2020","unstructured":"Zhu S, Fu Y, Zhu B, Zhang B, Wang J (2020) Pneumonitis induced by immune checkpoint inhibitors: from clinical data to translational investigation. Front Oncol 10:1785. https:\/\/doi.org\/10.3389\/fonc.2020.01785","journal-title":"Front Oncol"},{"key":"4362_CR9","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/j.resinv.2020.05.008","volume":"58","author":"K Sakamoto","year":"2020","unstructured":"Sakamoto K, Fukihara J, Morise M, Hashimoto N (2020) Clinical burden of immune checkpoint inhibitor-induced pneumonitis. Respir Investig 58:305\u2013319. https:\/\/doi.org\/10.1016\/j.resinv.2020.05.008","journal-title":"Respir Investig"},{"key":"4362_CR10","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.1148\/rg.2019190036","volume":"39","author":"KR Kalisz","year":"2019","unstructured":"Kalisz KR, Ramaiya NH, Laukamp KR, Gupta A (2019) Immune checkpoint inhibitor therapy-related pneumonitis: patterns and management. Radiographics 39:1923\u20131937. https:\/\/doi.org\/10.1148\/rg.2019190036","journal-title":"Radiographics"},{"key":"4362_CR11","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.1016\/j.jtho.2020.08.018","volume":"15","author":"S Ikeda","year":"2020","unstructured":"Ikeda S, Kato T, Kenmotsu H, Ogura T, Iwasawa S, Sato Y, Harada T, Kubota K, Tokito T, Okamoto I, Furuya N, Yokoyama T, Hosokawa S, Iwasawa T, Yamanaka T, Okamoto H (2020) A phase 2 study of atezolizumab for pretreated NSCLC with idiopathic interstitial pneumonitis. J Thorac Oncol 15:1935\u20131942. https:\/\/doi.org\/10.1016\/j.jtho.2020.08.018","journal-title":"J Thorac Oncol"},{"key":"4362_CR12","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.lungcan.2019.06.001","volume":"134","author":"D Fujimoto","year":"2019","unstructured":"Fujimoto D, Yomota M, Sekine A, Morita M, Morimoto T, Hosomi Y, Ogura T, Tomioka H, Tomii K (2019) Nivolumab for advanced non-small cell lung cancer patients with mild idiopathic interstitial pneumonia: a multicenter, open-label single-arm phase II trial. Lung Cancer 134:274\u2013278. https:\/\/doi.org\/10.1016\/j.lungcan.2019.06.001","journal-title":"Lung Cancer"},{"key":"4362_CR13","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1111\/1759-7714.12759","volume":"9","author":"O Kanai","year":"2018","unstructured":"Kanai O, Kim YH, Demura Y, Kanai M, Ito T, Fujita K, Yoshida H, Akai M, Mio T, Hirai T (2018) Efficacy and safety of nivolumab in non-small cell lung cancer with preexisting interstitial lung disease. Thorac Cancer 9:847\u2013855. https:\/\/doi.org\/10.1111\/1759-7714.12759","journal-title":"Thorac Cancer"},{"key":"4362_CR14","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1111\/1759-7714.13240","volume":"11","author":"H Wang","year":"2020","unstructured":"Wang H, Guo X, Zhou J, Li Y, Duan L, Si X, Zhang L, Liu X, Wang M, Shi J, Zhang L (2020) Clinical diagnosis and treatment of immune checkpoint inhibitor-associated pneumonitis. Thorac Cancer 11:191\u2013197. https:\/\/doi.org\/10.1111\/1759-7714.13240","journal-title":"Thorac Cancer"},{"key":"4362_CR15","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.570233","volume":"10","author":"F Barr\u00f3n","year":"2020","unstructured":"Barr\u00f3n F, S\u00e1nchez R, Arroyo-Hern\u00e1ndez M, Blanco C, Zatarain-Barr\u00f3n ZL, Catal\u00e1n R, Ramos-Ram\u00edrez M, Cardona AF, Flores-Estrada D, Arrieta O (2020) Risk of developing checkpoint immune pneumonitis and its effect on overall survival in non-small cell lung cancer patients previously treated with radiotherapy. Front Oncol 10:570233. https:\/\/doi.org\/10.3389\/fonc.2020.570233","journal-title":"Front Oncol"},{"key":"4362_CR16","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1001\/jamaoncol.2016.2453","volume":"2","author":"M Nishino","year":"2016","unstructured":"Nishino M, Giobbie-Hurder A, Hatabu H, Ramaiya NH, Hodi FS (2016) Incidence of programmed cell death 1 inhibitor-related pneumonitis in patients with advanced cancer: a systematic review and meta-analysis. JAMA Oncol 2:1607\u20131616. https:\/\/doi.org\/10.1001\/jamaoncol.2016.2453","journal-title":"JAMA Oncol"},{"key":"4362_CR17","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1111\/1759-7714.13364","volume":"11","author":"T Sugano","year":"2020","unstructured":"Sugano T, Seike M, Saito Y, Kashiwada T, Terasaki Y, Takano N, Hisakane K, Takahashi S, Tanaka T, Takeuchi S, Miyanaga A, Minegishi Y, Noro R, Kubota K, Gemma A (2020) Immune checkpoint inhibitor-associated interstitial lung diseases correlate with better prognosis in patients with advanced non-small-cell lung cancer. Thorac Cancer 11:1052\u20131060. https:\/\/doi.org\/10.1111\/1759-7714.13364","journal-title":"Thorac Cancer"},{"key":"4362_CR18","doi-asserted-by":"publisher","first-page":"58","DOI":"10.31662\/jmaj.2019-0005","volume":"3","author":"J Sugisaka","year":"2020","unstructured":"Sugisaka J, Toi Y, Taguri M, Kawashima Y, Aiba T, Kawana S, Saito R, Aso M, Tsurumi K, Suzuki K, Shimizu H, Ono H, Domeki Y, Terayama K, Nakamura A, Yamanda S, Kimura Y, Honda Y, Sugawara S (2020) Relationship between programmed cell death protein ligand 1 expression and immune-related adverse events in non-small-cell lung cancer patients treated with pembrolizumab. JMA J 3:58\u201366. https:\/\/doi.org\/10.31662\/jmaj.2019-0005","journal-title":"JMA J"},{"key":"4362_CR19","doi-asserted-by":"publisher","first-page":"1952","DOI":"10.1001\/jamaoncol.2020.5012","volume":"6","author":"B Shankar","year":"2020","unstructured":"Shankar B, Zhang J, Naqash AR, Forde PM, Feliciano JL, Marrone KA, Ettinger DS, Hann CL, Brahmer JR, Ricciuti B, Owen D, Toi Y, Walker P, Otterson GA, Patel SH, Sugawara S, Naidoo J (2020) Multisystem immune-related adverse events associated with immune checkpoint inhibitors for treatment of non-small cell lung cancer. JAMA Oncol 6:1952\u20131956. https:\/\/doi.org\/10.1001\/jamaoncol.2020.5012","journal-title":"JAMA Oncol"},{"key":"4362_CR20","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1001\/jamaoncol.2017.2925","volume":"4","author":"K Haratani","year":"2018","unstructured":"Haratani K, Hayashi H, Chiba Y, Kudo K, Yonesaka K, Kato R, Kaneda H, Hasegawa Y, Tanaka K, Takeda M, Nakagawa K (2018) Association of immune-related adverse events with nivolumab efficacy in non-small-cell lung cancer. JAMA Oncol 4:374\u2013378. https:\/\/doi.org\/10.1001\/jamaoncol.2017.2925","journal-title":"JAMA Oncol"},{"key":"4362_CR21","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1111\/cas.14715","volume":"112","author":"M Sata","year":"2021","unstructured":"Sata M, Sasaki S, Oikado K, Saito Y, Tominaga J, Sakai F, Kato T, Iwasawa T, Kenmotsu H, Kusumoto M, Baba T, Endo M, Fujiwara Y, Sugiura H, Yanagawa N, Ito Y, Sakamoto T, Ohe Y, Kuwano K (2021) Treatment and relapse of interstitial lung disease in nivolumab-treated patients with non-small cell lung cancer. Cancer Sci 112:1506\u20131513. https:\/\/doi.org\/10.1111\/cas.14715","journal-title":"Cancer Sci"},{"key":"4362_CR22","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1056\/nejmoa1801005","volume":"378","author":"L Gandhi","year":"2018","unstructured":"Gandhi L, Rodr\u00edguez-Abreu D, Gadgeel S, Esteban E, Felip E, De Angelis F, Domine M, Clingan P, Hochmair MJ, Powell SF, Cheng SY, Bischoff HG, Peled N, Grossi F, Jennens RR, Reck M, Hui R, Garon EB, Boyer M, Rubio-Viqueira B, Novello S, Kurata T, Gray JE, Vida J, Wei Z, Yang J, Raftopoulos H, Pietanza MC, Garassino MC, KEYNOTE-189 Investigators (2018) Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med 378:2078\u20132092. https:\/\/doi.org\/10.1056\/nejmoa1801005","journal-title":"N Engl J Med"},{"key":"4362_CR23","doi-asserted-by":"publisher","first-page":"2040","DOI":"10.1056\/nejmoa1810865","volume":"379","author":"L Paz-Ares","year":"2018","unstructured":"Paz-Ares L, Luft A, Vicente D, Tafreshi A, G\u00fcm\u00fc\u015f M, Mazi\u00e8res J, Hermes B, \u00c7ay \u015eenler F, Cs\u0151szi T, F\u00fcl\u00f6p A, Rodr\u00edguez-Cid J, Wilson J, Sugawara S, Kato T, Lee KH, Cheng Y, Novello S, Halmos B, Li X, Lubiniecki GM, Piperdi B, Kowalski DM, KEYNOTE-407 Investigators (2018) Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer. N Engl J Med 379:2040\u20132051. https:\/\/doi.org\/10.1056\/nejmoa1810865","journal-title":"N Engl J Med"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-021-04362-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00280-021-04362-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-021-04362-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,6]],"date-time":"2022-01-06T17:03:00Z","timestamp":1641488580000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00280-021-04362-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,14]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["4362"],"URL":"https:\/\/doi.org\/10.1007\/s00280-021-04362-7","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"type":"print","value":"0344-5704"},{"type":"electronic","value":"1432-0843"}],"subject":[],"published":{"date-parts":[[2021,10,14]]},"assertion":[{"value":"24 July 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 October 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that there is no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was approved by the institutional review board of Showa University Northern Yokohama Hospital, based on the ethical guidelines for medical and health research involving human subjects (approval no. 20H034).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"We obtained written informed consent from all the patients.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Written informed consent was obtained from the patients for anonymized information to be published in this article.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}